Battle for the GLP-1 Market: Novo Plummets – Hims Defies Legal Threat
Reading Time: 3 minutes
Novo Nordisk loses over 20% after profit warning – Hims is indirectly accused of undermining market shares. Legal action announced, yet Hims remains optimistic The Danish pharmaceutical giant Novo Nordisk triggered a major crash with its second profit warning this year. The stock fell more than 20% on Monday after the company significantly reduced its revenue and profit growth forecasts. The management cites the growing competition from "compounded" GLP-1 products, including those marketed through the Hims & Hers platform,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
